Systemic treatment of gastric cancer

Alessandro Morabito, Guido Carillio, Raffaele Longo

Research output: Contribution to journalArticlepeer-review


Treatment of gastric cancer is improved over the past years, but unanswered questions remain regarding the efficacy of systemic treatments in adjuvant, neoadjuvant and metastatic setting. It has not been definitively demonstrated the efficacy of adjuvant chemotherapy, that should not be adopted as a standard approach to localized gastric cancer. On the contrary, compelling evidence in support of perioperative chemotherapy with ECF regimen has been recently provided by the MAGIC trial, although many criticisms have been moved to this study. For metastatic setting, a recent meta-analysis showed a small, but significant survival benefit for combination vs single agent chemotherapy, and the V-325 trial demonstrated the superiority of a docetaxel containing regimen (DCF) over a doublet (CF). Finally, the results of ongoing clinical trials on a number of new molecular-targeted drugs should confirm their role in gastric cancer.

Original languageEnglish
Pages (from-to)216-234
Number of pages19
JournalCritical Reviews in Oncology/Hematology
Issue number3
Publication statusPublished - Jun 2009


  • Adjuvant therapy
  • Gastric cancer
  • Metastatic treatment
  • Neoadjuvant therapy
  • Target-based agents

ASJC Scopus subject areas

  • Geriatrics and Gerontology
  • Hematology
  • Oncology


Dive into the research topics of 'Systemic treatment of gastric cancer'. Together they form a unique fingerprint.

Cite this